Lysogene: Conversion of the Safeguard Proceedings Into Reorganization Proceedings
Lysogene (FR0013233475 LYS) LYS, a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces the conversion of the safeguard proceedings which has been in place since December 13, 2022 into reorganization proceedings.
As announced on January 6, 2023, in the absence of a solution to strengthen its financial situation and secure its cash runway during the safeguard proceedings, Lysogene together with the judicial administrator, filed a request with the Commercial Court of Nanterre for the conversion of the safeguard proceedings into reorganization proceedings. This request was examined and approved by the Commercial Court of Nanterre at the hearing of January 24, 2023.
In this context, Lysogene reminds that a bidding process for the purpose of finding buyers or investors has been published by the judicial administrator on January 6, 2023 and that the deadline for the submission of offers has been set by the latter to February 15, 2023 at 12:00 am.
Continue read on benzinga.com